Ultragenyx Pharmaceutical Inc.
UX111
Sanfilippo syndrome type A (MPS IIIA)
Resolved
151days ago
Catalyst readout · Feb 6, 2026
What's at stake
A key catalyst for UX111 (Sanfilippo syndrome type A (MPS IIIA)) is expected Feb 6, 2026.
Primary source
· SEC 8-K
verified 14h ago
“The data will be delivered in an oral presentation ... at the WORLDSymposium™ 2026 on Friday, February 6 at 8 a.m. PST.”